CSII News and Press, Cardiovascular Systems Inc. From 03/04/22

Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for peripheral and coronary vascular disease, today announced that it has appointed Jeffery W. Chambers, M.D., as Chief Medical Officer....

Cardiovascular Systems (NASDAQ:CSII) has collaborated with Innova Vascular to develop a full line of novel thrombectomy devices. Thrombectomy is an interventional procedure performed to remove blood clots from arteries and veins. The company intends to acquire and commercialize novel thr...

Mechanical and aspiration devices to treat peripheral vascular disease, deep vein thrombosis and pulmonary embolism Cardiovascular Systems, Inc. (CSI ® ) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatm...

Image source: The Motley Fool. Cardiovascular Systems (NASDAQ: CSII) Q2 2022 Earnings Call Feb 03, 2022 , 9:00 a.m. ET Operator Continue reading For further details see: Cardiovascular Systems (CSII) Q2 2022 Earnings Call Transcript

Cardiovascular Systems, Inc. (CSII) Q2 2022 Earnings Conference Call February 03, 2022, 09:00 AM ET Company Participants Jack Nielsen - VP, IR Scott Ward - Chairman, President, CEO Jeff Points - CFO Rhonda Robb - COO Conference Call Participants Mathew Blackman - Stifel Chris Pasquale - Gugge...

The following slide deck was published by Cardiovascular Systems, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Cardiovascular Systems, Inc. 2022 Q2 - Results - Earnings Call Presentation

Cardiovascular Systems press release (NASDAQ:CSII): Q2 GAAP EPS of -$0.23 misses by $0.09. Revenue of $59.1M (-7.9% Y/Y) misses by $3.56M. For the fiscal year ending June 30, 2022, CSI anticipates: Revenue of $235 million to $245 million from prior guidance of $265 million to $285 millio...

Conference Call Scheduled for Today, February 3, 2022, at 8:00 a.m. CT (9:00 a.m. ET) Revenues of $59.1 million increased 1.3% sequentially compared to first quarter this year and decreased 7.8% compared to second quarter last year Procedure volumes adversely impacte...

Cardiovascular Systems, Inc. (CSI ® ) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management plans to present and host inve...

Complementary technology to orbital atherectomy expands CSI’s vessel prep market opportunity Cardiovascular Systems, Inc. (CSI ® ) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for ...